You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic Review and meta-analysis
Tiotropium mist inhaler for COPD increases risk of mortality compared with placebo
  1. Felix S F Ram
  1. School of Health and Social Sciences, Massey University, Auckland, New Zealand
  1. Correspondence to: Felix S F Ram
    School of Health and Social Sciences, Massey University, Private Bag 102–904, North Shore, Auckland 0630, New Zealand; fsfram{at}yahoo.co.uk

https://doi.org/10.1136/ebm.2011.100171

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Singh S, Loke YK, Enright PL, et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215.OpenUrlAbstract/FREE Full Text

    Context

    Spiriva or tiotropium bromide (long-acting muscarinic receptor antagonist) is licensed for maintenance bronchodilator treatment in the management of chronic obstructive pulmonary disease (COPD) in 55 countries. Singh and colleagues conducted a systematic review of high-quality randomised controlled trials (RCTs) and assessed all-cause mortality in COPD patients using the Spiriva Respimat Soft Mist Inhaler (RSMI) compared with placebo.

    Methods

    The authors conducted a systematic review of high-quality RCTs with 6522 patients. All included trials were of parallel design with study duration varying from 12 to 52 weeks. The authors conducted various sensitivity analyses to test the robustness of their findings which included using random effects …

    View Full Text

    Footnotes

    • Competing interests None.